Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Summary
The purpose of this study is to assess if argon plasma coagulation (APC) is a safe and well tolerated treatment method for anal intraepithelial neoplasia (AIN) grade 2/3 in HIV-positive men having sex with men (MSM).
Official title: A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men
Key Details
Gender
MALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2007-02
Completion Date
2016-07
Last Updated
2026-08-14
Healthy Volunteers
No
Conditions
Interventions
Argon Plasma Coagulation
Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
Locations (2)
Notre-Dame Hospital (Centre Hospitalier de l'Université de Montréal)
Montreal, Quebec, Canada
Royal Victoria Hospital (McGill University Health Center)
Montreal, Quebec, Canada